ebook Munafa Stock Market Course + Intraday & FNO calls  

       

Denali Therapeutics (DNLI) Technical (Analysis) Reports Denali Therapeutics ["Technical Analysis"] Reports -USA Stock Exchange MunafaSutra.com

Complete & easy to understand technical analysis of Denali Therapeutics (DNLI)

Technical Analysis Report for USA stock DNLI Denali Therapeutics. Dated: 12 Dec 2025 Updated Daily. Stock trades under Health Care Deals in Biotechnology Biological Products No Diagnostic Substances in USA stock exchange

If you are looking for Tomorrow's Movement Predictions for USA stock DNLI Denali Therapeutics then click here. or read Experts views on Denali Therapeutics or Forecast & share price targets of Denali Therapeutics

Denali Therapeutics Opened at 17.41 and Closed at: 17.98, which is 3.39% of previous session's close. It moved within a range of 17.24 and 18.30
The session was a Bullish session with an average volume of 1400500, which is -114.14% of previous session's volumes.

  • There is some positive change in the short term trend, but its too soon to jump onto conclusions.
  • The stock has shown an up move, and its mid term trend is also positive and in an uptrend.
  • Even though the stock has shown an up move, but the long term trend of the stock remains negative and in a downtrend.

Support for tomorrow is 17.61 and resistance for tomorrow is 18.67
These support and resistance points are valid for the first 5-15 minutes charts

Above are simple pivot point calculations. For a list of much stronger support and resistance levels click here. These are way more stronger support and resistance levels, and mark trend reversals and are Support & Resistance levels recommended by experts.

Support for tomorrow's hourly charts is 17.38, 16.78 resistance for tomorrow's hourly charts is 18.44, 18.9

10 Day SMA for Denali Therapeutics (DNLI) is 18.73 and stock is trading below these levels. This is not a good sign for its short term trend

20 Day SMA for Denali Therapeutics (DNLI) is 18.43 and the stock is trading below these levels. This is not a good sign for its mid term trend

50 Day SMA for Denali Therapeutics (DNLI) is 16.97 and the stock is trading above these levels. This is a good sign for its mid to long term trend

100 Day SMA is 15.68 and the stock is trading above these levels. This is a good sign for its long term trend

200 Day SMA Denali Therapeutics is 15 and stock is trading above these levels. This is a good sign for its long term trend

20 DMA of Denali Therapeutics is at 18.43 and 200 DMA is at 15, while 50 DMA and 100 DMA are at 16.97 and 15.68 respectively

Denali Therapeutics (DNLI) moving average of 20 SMA is at 18.43 and 20 EMA is at 18.23

Denali Therapeutics (DNLI) moving average of 50 SMA is at 16.97 and 50 EMA is at 17.18

Denali Therapeutics (DNLI) moving average of 100 SMA is at 15.68 and 100 EMA is at 16.37

Denali Therapeutics (DNLI) moving average of 200 SMA is at 15 and 200 EMA is at 16.72

Pfizer Inc has performed better than Denali Therapeutics in short term. You could have earned much better returns by investing in Pfizer Inc, about 0.05% more returns!

Denali Therapeutics has performed better than Fresenius Medical in short term. Holding Denali Therapeutics could be a better choice for now!

Denali Therapeutics has performed better than Boston Scientific in short term. Holding Denali Therapeutics could be a better choice for now!

Denali Therapeutics has performed better than Abbvie Inc in short term. Holding Denali Therapeutics could be a better choice for now!

China Sxt has performed better than Denali Therapeutics in short term. You could have earned much better returns by investing in China Sxt, about 3.72% more returns!

Proqr Therapeutics has performed better than Denali Therapeutics in short term. You could have earned much better returns by investing in Proqr Therapeutics, about 4.27% more returns!

Denali Therapeutics has performed better than Minerva Neurosciences in short term. Holding Denali Therapeutics could be a better choice for now!

Mesoblast has performed better than Denali Therapeutics in short term. You could have earned much better returns by investing in Mesoblast, about 19.24% more returns!

Microbot Medical has performed better than Denali Therapeutics in short term. You could have earned much better returns by investing in Microbot Medical, about 13.33% more returns!

Icon Plc has performed better than Denali Therapeutics in short term. You could have earned much better returns by investing in Icon Plc, about 11.95% more returns!

Denali Therapeutics has performed better than Halozyme Therapeutics in short term. Holding Denali Therapeutics could be a better choice for now!

Denali Therapeutics has performed better than Galapagos Nv in short term. Holding Denali Therapeutics could be a better choice for now!

Denali Therapeutics has performed better than Ensign Group in short term. Holding Denali Therapeutics could be a better choice for now!

Celldex Therapeutics has performed better than Denali Therapeutics in short term. You could have earned much better returns by investing in Celldex Therapeutics, about 4.57% more returns!

Denali Therapeutics has performed better than Audentes Therapeutics in short term. Holding Denali Therapeutics could be a better choice for now!

Atricure Inc has performed better than Denali Therapeutics in short term. You could have earned much better returns by investing in Atricure Inc, about 25.71% more returns!

Denali Therapeutics Technical analysis of indicators

Price action analysis of Denali Therapeutics (DNLI) based on a short term time period is definitely negative. This means that there is a strong downtrend in the stock for given time period. Sellers are extremely active on this stock.

ADX buy sell signal for Denali Therapeutics stock for short term is SELL. Signal strength is Weak and stock is losing momentum.

MACD generated a SELL signal for Denali Therapeutics in short term but the sell signal is initial and weak.

Denali Therapeutics Stock is trading near its recent LOWS in short term which reflects strong selling momentum. Bears are getting stronger in this stock.

Ichimoku cloud is of green color and prices are in or below the green cloud Prices appear to be moving up

CCI has generated a buy signal for Denali Therapeutics in short term but BUY signal is weak.

RSI is generating a BUY signal in short term and the buying is gaining momentum.

MRSI is in positive zone. This is a BUY zone

Stock of Denali Therapeutics is picking up buying momentum according to indicator.

Volume based indicators are showing selling momentum.

Volume Weighted Averaged Price (VWAP) for short term is 18.5 and Denali Therapeutics DNLI stock is trading below this level. This means that stock is falling with high volumes. VWAP is falling down

People seem to be coming out and selling the Denali Therapeutics DNLI stock. Volume based technical analysis of Denali Therapeutics DNLI stock is negative.

Denali Therapeutics Stock has given negative returns over a short term period. Returns for a longer term period have been positive

Force Index is moving in a negative zone, which indicates selling momentum for short term... Selling momentum is getting weaker.

Tomorrow's Predictions

You should also read Tomorrow's Movement Predictions for USA stock DNLI Denali Therapeutics These predictions are based on various factors, are easy to understand, and upto 75% accurate!

And DNLI Experts View which covers a lot of information including buying and selling signals

DNLI future forecast & share price targets

You can also take a look at the Charts and indicator analysis here Announcements & NEWS by Denali Therapeutics or View Candle Stick Charts here

Chart Denali Therapeutics (DNLI)  Technical (Analysis) Reports Denali Therapeutics [

Videos related to: Denali Therapeutics (DNLI) Technical (Analysis) Reports Denali Therapeutics ["Technical Analysis"] Reports -USA Stock Exchange MunafaSutra.com

Hindi Basics How To Trade In FnO Futures Options Stock Market

Hindi Video The Truth Of Stock Markets That Everyone Is Hiding From You

Denali Therapeutics (DNLI)  Technical (Analysis) Reports Denali Therapeutics [

 

Back to top